The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: Analysis of the Scientific Registry of Transplant Recipients (SRTR) database

Clinical Transplantation

Volumn 25, Issue 4, 2011, Pages

  Snydman, David R ^a   Kistler, Kristin D ^b   Ulsh, Paula ^c   Bergman, Garrett E ^c   Vensak, Judith ^c   Morris, Jonathan ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ProSanos Corporation   (United States)

^c CSL Behring LLC   (United States)

Author keywords

Antiviral agents; Cytomegalovirus; Cytomegalovirus specific hyperimmune globulin; Graft survival; Heart transplantation

Indexed keywords

ANTIVIRUS AGENT; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DATA BASE; DEATH; DISEASE REGISTRY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HOSPITAL DISCHARGE; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE;

ADULT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SURVIVAL RATE; TISSUE DONORS; TREATMENT OUTCOME;

EID: 80051704381     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01459.x     Document Type: Article

References (25)

1. Haddad F, Deuse T, Pham M et al. Changing trends in infectious disease in heart transplantation. J Heart Lung Transplant 2010: 29: 306.
2. McCarthy PM, Starnes VA, Shumway NE. Heart and heart-lung transplantation: the Stanford experience. Clin Transpl 1989: 63.
3. Van De Beek D, Kremers WK, Del Pozo JL et al. Effect of infectious diseases on outcome after heart transplant. Mayo Clin Proc 2008: 83: 304.
4. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson B, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989: 261: 3561.
5. Graham JA, Wilkinson RA, Hirohashi T et al. Viral infection induces de novo lesions of coronary allograft vasculopathy through a natural killer cell-dependent pathway. Am J Transplant 2009: 9: 2479.
6. Kocher AA, Bonaros N, Dunkler D et al. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. J Heart Lung Transplant 2003: 22: 250.
7. Petrakopoulou P, Kübrich M, Pehlivanli S et al. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation 2004: 110: 207.
8. Potena L, Grigioni F, Ortolani P et al. Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. Transplantation 2003: 75: 839.
9. Vrtovec B, Thomas CD, Radovancevic R, Frazier OH, Radovancevic B. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients. J Heart Lung Transplant 2004: 23: 461.
10. Bonaros NE, Kocher A, Dunkler D et al. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. Transplantation 2004: 77: 890.
11. Potena L, Holweg CT, Chin C et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006: 82: 398.
12. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant 2008: 22: 89.
13. Wittes JT, Kelly A, Plante KM. Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients. Transplant Proc 1996: 28: 17.
14. Hodson EM, Jones CA, Strippoli GF, Webster AC, Craig JC. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2007: 18: CD005129.
15. Couchoud C, Cucherat M, Haugh M, Pouteil-Noble C. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 1998: 65: 641.
16. Hodson EM, Barclay PG, Craig JC et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2005: 4: CD003774.
17. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005: 143: 870.
18. Aguado JM, Gomez-Sanchez MA, Lumbreras C et al. Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrob Agents Chemother 1995: 39: 1643.
19. Valantine HA, Luikart H, Doyle R et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001: 72: 1647.
20. Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010: 87: 779.
21. Taylor DO, Edwards LB, Aurora P et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report-2008. J Heart Lung Transplant 2008: 27: 943.
22. Fateh-Moghadam S, Bocksch W, Wessely R, Jager G, Hetzer R, Gawaz M. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation 2003: 76: 1470.
23. Arora S, Andreassen A, Simonsen S et al. Prognostic importance of renal function 1year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy. Transplantation 2007: 84: 149.
24. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003: 349: 931.
25. Navarro-Manchón J, Martínez-Dolz L, Almenar Bonet L et al. Predictors of renal dysfunction at 1year in heart transplant patients. Transplantation 2010: 89: 977.